Acadia Share Price Peaks After Positive Parkinson’s Antipsychotic Trial


Acadia Pharmaceuticals’ share price has more than doubled this year on news that its experimental antipsychotic pimavanserin reduced symptoms such as “hallucinations and delusions of jealousy” by more than a third compared to a reduction of 18.5% in patients receiving a placebo, improved the quality of nighttime sleep, and reduced the burden on caregivers, suggesting an “attractive commercial opportunity” according to a stock analyst. The company acknowledged  that antipsychotics can increase the risk of death as well as side effects such as the loss of motor control, but that pimavanserin did not affect patients’ motor control.

Article →

Of further interest:

Acadia Pharma: progress with anti-psychotic drug (Marketwatch)

Previous articleNY Supreme Court Awards $1.5 M in Antidepressant-Related Suicide
Next articleDeclining Use of ECT in U.S. Hospitals
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].


  1. This is exactly what they said about the so called atypicals when they came out and most doctors still believe it. When it takes 20 years for doctors to even begin to acknowledge lies, pharmaceutical companies will find ways to lie.

    Even if it does turn out that it doesn’t cause movement disorders, it’s bound to cause a whole bunch of other problems anyway. It’s also very doubtful that it could actually even work since the biological causes of these so called symptoms are still completely unknown. The odds of stumbling onto a corrective for an unknown malfunction in the most complicated organ there is? Probably no better than one in a quadrillion.

    Report comment